Table 1.
Baseline characteristics of included patients
| Patients | N = 1657 |
|---|---|
| Participating centers, n | 27 |
| Age, median (min-max), y | 80 (47-100) |
| Males, n (%) | 896 (54.1) |
| BMI, median (min-max) | 26.2 (14.9-68.1) |
| Hemoglobin, median (min-max), (g/dL) | 13.3 (8.0-18.8) |
| Platelets, median (min-max), (×103/μL) | 218 (52-700) |
| Creatinine clearance, median (min-max), mL/min | 58.0 (13-246) |
| History of cerebrovascular ischemic disease/peripheral arterial emboli, n (%) | 186 (11.2) |
| History of cardiovascular disease, n (%) | 284 (17.1) |
| History of gastrointestinal bleeding, n (%) | 22 (1.3) |
| History of cancer, n (%) | 227 (13.7) |
| Hypertension, n (%) | 1472 (88.8) |
| Diabetes, n (%) | 375 (22.6) |
| Liver cirrhosis, n (%) | 14 (0.8) |
| Chronic kidney disease, n (%) | 197 (11.9) |
| Hypothyroidism/hyperthyroidism, n (%) | 165 (10.0)/62 (3.7) |
| Smokers, n (%) | 190 (11.5) |
| Alcohol intake, n (%) | 58 (3.5) |
| Mental disorders, n (%) | 52 (3.1) |
| Family/social support, n (%) | 1410 (85.1) |
| Drug daily dose, n (%) | |
| Apixaban [standard dose] [low dose] | 521 (31.5) [336 (65.5)] [185 (35.5)] |
| Dabigatran [standard dose] [low dose] | 221 (13.3) [100 (45.3)] [121 (54.7)] |
| Edoxaban [standard dose] [low dose] | 583 (35.2) [283 (48.6)] [300 (51.4)] |
| Rivaroxaban [standard dose] [low dose] | 332 (20.0) [238 (71.7)] [94 (28.3)] |
| Prescribing accuracy of DOACs18 | |
| Appropriate, n (%) | 1441 (87.0) |
| Inappropriate low dose | 140 (8.4) |
| Inappropriate standard dose | 76 (4.6) |
| Prior VKA treatment, n (%) | 512 (30.9) |
| Use of antiplatelet drugs, n (%) | 382 (23.0) |
| Number of associated drugs, median (min-max) | 3 (0-9) |
| Antihypertensives, n (%) | 933 (56.3) |
| Antiarrhythmics, n (%) | 695 (41.9) |
| Gastroprotectors, n (%) | 655 (39.5) |
| Antidyslipidemics, n (%) | 585 (35.3) |
| Thyroid disease drugs, n (%) | 210 (12.7) |
| Anxiolytics, n (%) | 175 (10.6) |
| Psychotropics, n (%) | 137 (8.3) |
| Painkillers, n (%) | 67 (4.0) |
| Steroids, n (%) | 47 (2.8) |
| Antiepileptic drugs, n (%) | 28 (1.7) |
| Nitrates, n (%) | 13 (0.8) |
| Immunosuppressants, n (%) | 11 (0.7) |
| Antivirals, n (%) | 7 (0.4) |
| Polytherapy ≥3, n (%) | 1196 (72.2) |
| CHA2DS2VASc score, median (min-max) | 4 (0-8) |
| CHA2DS2VASc score of ≥4, n (%) | 1072 (64.7) |
| HAS-BLED in all patients, median (min-max) | 3 (0-6) |
| HAS-BLED score ≥3, n (%) | 996 (60.1) |
BMI, body mass index; max, maximum; min, minimum; VKA, vitamin K antagonist.